[Duration of action of trandolapril in mild to moderate hypertensive patients evaluated by ambulatory measurement of blood pressure].

The duration of the antihypertensive action of transdolapril, a new angiotensin converting enzyme inhibitor, was studied in 23 patients using ambulatory blood pressure monitoring (ABPM) over 48 hours. After a 20-day placebo period (D1 to D20), mild to moderate hypertensive patients received 2 mg trandolapril once daily for 30 days (D21 to D50). The first 24-hour ABPM recording was performed on day 14, during the placebo run-in period. Two additional recordings were done successively on days 50 and 51 corresponding to a normal dosing day and a following day with a simulated missed dose, respectively. The three blood pressure recordings (placebo, treatment, missed dose) were compared. The average 24-hour systolic (SBP) and diastolic (DBP) blood pressure were significantly decreased by trandolapril. The mean +/- s.d. decrease between day 14 and day 50 were - 8.0 +/- 7.2 mmHg for the DBP and -13.3 +/- 7.8 mmHg for the SBP. Blood pressure was also consistently decreased during the daytime period (-8.7 +/- 7.9 mmHg for the DBP and - 15.6 +/- 8.5 mmHg for the SBP), nighttime period (-5.6 +/- 9.1 mmHg for the DBP and - 8.5 +/- 11.3 mmHg for the SBP) and early morning (- 12.3 +/- 9.7 mmHg for the DBP and - 15.9 +/- 15.1 mmHg for the SBP). The normal circadian pattern of blood pressure was maintained under treatment. The antihypertensive effect of trandolapril was sustained beyond 24 hours after the last intake: there were no significant difference beetween days 50 and 51 in terms of 24-hour, daytime and nighttime average blood pressure.(ABSTRACT TRUNCATED AT 250 WORDS)

RCT Entities:   Population Interventions Outcomes